A case of a 66-year-old Japanese man developed therapy-related megakaryoblastic leukemia with pituitary involvement after chemotherapy for non-Hodgkin's lymphoma. Alkylating agents had been administered for the treatment of non-Hodgkin's lymphomaand 6 years later, megakaryoblastic leukemia with myelofibrosis and myelodysplasia developed. The blast cells expressed CD41,and immatureantigens also. These findings were compatible with therapy-related megakaryoblastic leukemia. An autopsy revealed blast-cell infiltration into multiple organs including the posterior pituitary lobe. Therapy-related megakaryoblastic leukemia is very rare, and pituitary involvement may be associated with immaturity of blast cells. (Internal Medicine 38: 904-909, 1999) 
Introduction
Therapy-related myelodysplastic syndrome and therapy-related leukemia (TRL) are knownto develop after exposure to cytotoxic agents and/or radiotherapy. Twotypes of TRLcases have been identified that occur following treatment with alkylating agents or topoisomerase II inhibitors, especially etoposide (1) . Acute myeloid leukemia (AML) cases developing after exposure to etoposide, has been recognized as often having translocations involving chromosome I lq23, monocytic phenotypes, and an acute presentation with substantial blast counts (1) . TRLrelated to prior treatment with alkylating agents is characterized by the initial development of myelodysplasia, unbalanced chromosomalaberrations such as complete or partial deletions of chromosomes 5 and/or 7, and progression to leukemia 4 to 5 years after chemotherapy (2) . As these cases evolve to moreovert leukemia, features characteristic of FrenchAmerican-British (FAB) subtypes Ml, M2, or M4are common and most cases demonstrate trilineage involvement (2, 3) . Acute megakaryoblastic leukemia, designated AML-M7, was added to the FABclassification in 1985 (4) . The diagnosis of AML-M7 requires an ultrastructural demonstration of platelet peroxidase or immunological demonstration of CD41, CD42, or factor VIII (4). Clinically, AML-M7 in adults has occurred as a de-novo form, leukemic transformation in myeloproliferative disorder or myelodysplastic syndrome, and it is therapyrelated. Several such therapy-related megakaryoblastic leukemia cases are described in the literature (5) (6) (7) (8) (9) . The present case is the first report of acute megakaryoblastic leukemia following treatment for non-Hodgkin's lymphoma (NHL) with combination chemotherapy including alkylating agents and showing blast-cell infiltration into multiple organs, including the pi tuitary.
Case Report
In June 1987, a 61-year-old man presented with NHLstage IVa (classification of Working Formulation: diffuse small cleaved). The right cervical lymph node biopsy specimen was positive for B cell antigen (CD20) expression and negative for T cell antigen (UCHL-1) and cyclin Dl expression. He received a combination chemotherapyconsisting of vincristine, cyclophosphamide, and doxorubicin by intravenous administration and prednisolone orally (CHOP). The patient was treated with two courses of CHOPtherapy followed by another combination chemotherapy, MACOP-B , which consists of intravenous cyclophosphamide, vincristine, doxorubicin, methotrexate, and bleomycin, and oral prednisolone. Accumulated doses of cy-Therapy-related AML(M7) successful due to a dry tap, and bone marrow biopsy revealed moderate reticulin fibrosis and blast cell proliferation that exhibited various sizes of blast cells. He received prednisolone because myelofibrosis with myelodysplasia was diagnosed after the bone marrowbiopsy. In spite of therapy, pancytopenia developed; therefore the patient underwent splenectomy to resolve hypersplenism and to investigate lymphoma recurrence. Pathological examination of the spleen showed megakaryoblastic cell proliferation and no lymphomacells. After splenectomy, the patient became transfusion-dependent because the pancytopenia gradually progressed with blast cell proliferation. In September 1993, the patient's white blood cell count was 4.4xlO9// with 67.0% blast cells ( Fig. 1 ), which were positive for periodic acid-schiff and negative for myeloperoxidase, Sudan black B, naphthol-ASD-chloroacetate esterase, and anaphthyl butyrate esterase. Flowcytometric analysis of mononuclear cells revealed positivity for CD7, CD33, CD34, CD41, and HLA-DR, and negativity for CD2, CD3, CD4, CD5, CD8, CD10, CD13, CD19, and CD20 (Table 1) . T cell receptor gene rearrangement could not be detected by Southern blot analysis of blast cells in peripheral blood. Cytogenetic analysis of blast cells in peripheral blood and spleen cells revealed normal karyotypes without deletion of chromosomes 5 or 7. Immunohistological investigation of blast cells by electron microscopy showed that 12%of blast cells were positive for CD41with platelet peroxidase (PPO) reaction (Fig. 2) , 48% of blast cells were positive for CD41 without PPO reaction (Fig. 3) , 40% of blast cells were positive for CD7with (Fig. 4) or without PPO reaction, and some blast cells were found to have demarcation membranes and alpha granules (Figs. 2, 3 ). These results were interpreted as fulfilling the diagnostic criteria for acute megakaryoblastic leukemia (FAB classification M7). After receiving full information concerning his prognosis and the therapeutic options, the patient expressed a strong refusal of further treatment for leukemia; so he was given only treatment for his symptoms. In January 1994, he developed peripheral lymphadenopathy and hepatomegaly, increased 
Discussion
The present case report is an example of therapy-related megakaryoblastic leukemia after chemotherapy for NHL.The clinical course involved the occurrence of leukemia about 6 years after administration of alkylating agents. At this 6-year point, myelodysplasia and myelofibrosis, which are knownas therapy-related leukemia features, were observed. These findings may be sufficient for the diagnosis of therapy-related leukemia. The patient presented with NHLstage IVa (classification of Working Formulation: diffuse small cleaved); however, lymphomacells which revealed B cell phenotype without cyclin D l in immunohistological analysis, could not be detected when myelodysplasia and myelofibrosis developed. Unfortunately, megakaryoblastic leukemia was not identified on his second admission in June 1993, so the patient underwent splenectomy. After splenectomy, he became transfusion-dependent because his spleen showed extramedullary hemopoiesis with blast cell infiltration. Acute megakaryoblastic leukemia is a rare subtype of therapy-related leukemia and only a few cases have been reported (5) (6) (7) (8) (9) . TRL that follows treatment with alkylating agents exhibits FABsubtype of Ml, M2, or M4 in half of the cases, and some cases have been unclassifiable. Of the 589 cases of FAB subtype in TRL that have been reported (10) (11) (12) (13) (14) , therapyrelated megakaryoblastic leukemia (M7) is extremely rare (0.7%) ( Table 2) . Recently, TRL in Japan was analyzed in a multi-institution study. Amongthe 301 cases of adult TRLand myelodysplastic syndrome diagnosed, only 4 were therapy-related megakaryoblastic leukemia and 10 were unclassifiable (14) . Only one case of therapy-related megakaryoblastic leukemia following treatment of NHLhas been reported (15 (12) pointed out that the FAB classification criteria for diagnosis of this leukemia are not satisfied because the proliferative process in TRLcases involved multiple cell lines and appeared to bridge several classifications. This feature was supported by other reports in which approximately 10% ofTRL cases could not be classified (10) (11) (12) (13) (14) . Tabilio et al (6) reported that megakaryoblastic proliferation associated with blasts of other cell lines (erythroblast or myeloblast) was observed in TRLassociated with myelofibrosis and that TRLmay involve all marrow cell lines; however, the terminal evolution may be characterized by a cellular clone that has acquired a proliferative advantage. In the present case, myelodysplastic appearance as trilineage involvement was observed, and leukemic cells were shown to be heterogeneous by immunoelectron and immunophenotyping analysis (positive myeloid antigen, CD33). If only morphological analysis had been performed, the leukemia cells might have been classified as of unknown origin.
Second, many investigators have commentedupon the difficulty in diagnosing TRL according to the FABcriteria, as the leukemias demonstrate reticulin fibrosis (2, 3, 12, 13) . Since bone marrowfibrosis exists in such cases, along with the consequent difficulty in obtaining samples, cytogenetic studies have not been performed frequently. The development of more precise immunohistological, electronmicroscopic, and cytogenetic studies now increases the possibility of precisely determining the blast cell origin of TRL. This means that previously unclassifiable TRLcases with myelofibrosis may increasingly be distinguished as megakaryoblastic leukemia. Interestingly, Cuneo et al (17) reported that megakaryoblastic leukemia is associated with chromosome 5/5q or 7/7q deletion, which are frequent deletions in TRL. Karp and Smith (1) noted that cases of TRLdue to alkylating agents presented with myelodysplastic syndromethat culminate in acute leukemia, often with erythroid (M6) or megakaryocytic (M7) phenotype with concomitant myelofibrosis.
In the immunoelectron analysis of the present case, blast cells were positive for CD41with or without PPO activity. In addition, a portion of the blast cells was positive for CD7with or without PPOactivity. In vitro experiment on megakaryoblastic cells showed increased CD41 positivity and decreased CD7after culture with a stimulant (18) . This finding may be correlated with our results of immunoelectron analysis. On the basis of this findings, megakaryoblastic leukemia cells seem to be heterogeneous and capable of differentiation in vivo. The blast cells also expressed CD34, knownas multipotent stem cell marker, which suggests that CD7-positive megakaryoblastic leukemia may include cases in which leukemic cells originated in the cells arrested at an early stage of a megakaryocytic differentiation pathway. The present case has unusual characteristics compared to typical de novo AMLM7patients. Acute myeloid leukemia may infiltrate more rarely than lymphoid leukemia into the central nervous system (CNS), but there have been no reports of posterior pituitary lobe involvement in megakaryoblastic leukemia. Only one case was described with peripheral nerve involvement in CD7-positive acute megakaryoblastic leukemia (19) . CNSinvolvement is known to be frequent in CD7-positive AMLassociated with immature leukemic cells (20) . Yumura-Yagi et al (21) reported that CD7is expressed most frequently in acute megakaryoblastic leukemia and that the blast cells originate from very immature cells. In the present case, the blast cells expressed CD7and CD34, and this immature surface antigen expression mayhave been related to the pituitary involvement, since the posterior lobe and the stalk are of neural origin. Our patient showed no symptomof diabetes insipidus (DI) such as polyuria, thirst or electrolyte abnormality in the terminal phase in spite of the posterior pituitary lobe involvement. Although pituitary gland infiltration of acute myelogenous leukemia is occasionally described, there have been few reports of DI caused by direct invasion of leukemic cells into the pituitary or hypothalamus (22) . This may be attributed to the fact that total destruction of the posterior lobe or about 50% of the fibrils of the hypothalamo-hypophyseal pathway is needed for the development of clinical manifestations of DI. Dilek et al (23) have suggested that pituitary infiltration ofAMLdoes not always cause DI, and DI most likely develops secondaryto the stasis or emboliformationcaused by hyperleukocytosis. To the best of our knowledge, this is the first case of therapy-related megakaryoblastic leukemia with pituitary involvement. The findings in this case study suggest that AMLcases that might be immature megakaryoblastic leukemia should be analyzed for pituitary infiltration.
